SIBN vs. EMBC, TMCI, SILK, ATRI, IRMD, KIDS, OFIX, NVRO, OSUR, and FNA
Should you be buying SI-BONE stock or one of its competitors? The main competitors of SI-BONE include Embecta (EMBC), Treace Medical Concepts (TMCI), Silk Road Medical (SILK), Atrion (ATRI), Iradimed (IRMD), OrthoPediatrics (KIDS), Orthofix Medical (OFIX), Nevro (NVRO), OraSure Technologies (OSUR), and Paragon 28 (FNA). These companies are all part of the "surgical & medical instruments" industry.
SI-BONE (NASDAQ:SIBN) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
In the previous week, Embecta had 4 more articles in the media than SI-BONE. MarketBeat recorded 4 mentions for Embecta and 0 mentions for SI-BONE. Embecta's average media sentiment score of 0.22 beat SI-BONE's score of 0.00 indicating that Embecta is being referred to more favorably in the news media.
98.1% of SI-BONE shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 5.4% of SI-BONE shares are owned by insiders. Comparatively, 0.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Embecta has a net margin of 4.93% compared to SI-BONE's net margin of -31.20%. Embecta's return on equity of -18.66% beat SI-BONE's return on equity.
SI-BONE has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Embecta has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
SI-BONE currently has a consensus price target of $26.67, suggesting a potential upside of 84.54%. Embecta has a consensus price target of $16.00, suggesting a potential upside of 52.38%. Given SI-BONE's stronger consensus rating and higher probable upside, equities analysts plainly believe SI-BONE is more favorable than Embecta.
Embecta has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
SI-BONE received 157 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 66.81% of users gave SI-BONE an outperform vote while only 0.00% of users gave Embecta an outperform vote.
Summary
SI-BONE and Embecta tied by winning 9 of the 18 factors compared between the two stocks.
Get SI-BONE News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
